![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy, safety and tolerability of dual therapy with raltegravir 400mg bid and atazanavir 200mg bid in antiretroviral experienced patients.
|
|
|
Reported by Jules Levin
5th IAS Capetown July 19-22 2009
D. Ripamonti1,2, F. Maggiolo1,2, E. Bombana2, G. Gregis1,2, G. Quinzan1,2, A. Callegaro3and F. Suter1,2
Antiviral Research Unit1, Infectious Diseases Unit2, Microbiology and Virology Unit3at Ospedali Riuniti di Bergamo, Italy
![image002.gif](../images/080409/080409-2/image002.gif)
![image004.gif](../images/080409/080409-2/image004.gif)
![image006.gif](../images/080409/080409-2/image006.gif)
RESULTS
Table 1: Baseline characteristics
![image008.gif](../images/080409/080409-2/image008.gif)
![image010.gif](../images/080409/080409-2/image010.gif)
![image012.gif](../images/080409/080409-2/image012.gif)
![image014.gif](../images/080409/080409-2/image014.gif)
![image016.gif](../images/080409/080409-2/image016.gif)
![image018.gif](../images/080409/080409-2/image018.gif)
![image020.gif](../images/080409/080409-2/image020.gif)
![image022.gif](../images/080409/080409-2/image022.gif)
![image024.gif](../images/080409/080409-2/image024.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|